   
  
G/MA/QR/N/EU/5/Add.3  
 
31 March  2021 
(21-2666) Page: 1/5 
Committee on Market Access  Original: English  
 
  
NOTIFICATION PURSUANT TO THE DECISION ON NOTIFICATION  PROCEDURE S 
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)  
 EUROPEAN UNION 
Addendum   
The following communication, dated 29 March 2021 , is being circulated at the request of the 
delegation of the European Union . 
 
A. Notifying Member : European Union  
B. Date of notification : 29 March 2021  
C. First time notification:  
 Yes 
 No, last notification was made in (doc. symbol ): G/MA/QR/N/EU/5, G/MA/QR/N/EU/5/Add.1 
and G/MA/QR/N/EU/5/Add.2  
D. Type of notification:  
 1. Complete (i.e. notification of all quantitative restrictions in force ) 
 2. Changes to a notification previously made in (doc symbol)  which are of the following 
nature : 
  2.1 Introduction of new restrictions, as listed in Section 1. 
  2.2 Elimination of restrictions, as described in G below . 
  2.3 Modification of a previously notified restriction, as described in Section 1. 
 3. Reverse notification of restrictions maintained by (Member ):  
E. The notification provides information for the follo wing biennial period 
(e.g.  2012 -2014): 2020-2022 and relates to restrictions in force as of 26.03 .2021  
F. This notification contains information* relating to:  
 Section  1: List of quantitative restrictions that are currently in force . 
 Section  2: Cross -reference to other WT O notifications with information on quantitative 
restrictions that are currently in force and additional information . 
 
* In English  only. G/MA/QR/N/EU/5/Add.3  
 
- 2 - 
 
  G. Comments of a general nature, including a description of the elimination of 
restrictions notified under D.2.2 and the date they ceased to be in force.   
 The EU is notifying changes to the export authorisation requirement for Covid -19 vaccines, 
applicable to exports of vaccines produced by companies with which the EU has Advance 
Purchase Agreements (notified in G/MA/QR/N/EU/5/Add.1  and Add.2 ). Based on the 
principle of international solidarity, exports to more than 100 countries continue to be 
exempted from the measure, such as, in particular, exports related to COVAX  and in the 
context of a humanitarian emergenc y response.   
 
 
 
 
 
 
 
 
  
  G/MA/QR/N/EU/5/Add.3  
 
- 3 - Section  1: List of quantitative restrictions that are currently in force  
 
 
QR 
No.  General 
description 
of the 
restriction  Type of 
restriction  Tariff line 
code  (s) 
affected, based 
on HS (2017)  Detailed Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. Other 
International 
Commitments  National legal basis and 
entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
1 Export 
authorisation 
for COVID -19 
vaccines  
 NAL-X ex 3002 20  
ex 2933 99  
ex 2934 99  
ex 3002 90  
ex 3504 00  Vaccines against SARS -
related coronaviruses 
(SARS -CoV species), 
irrespective of their 
packaging, and active 
substances including 
master and working cell 
banks used for the 
manufacture of such 
vaccines  Protection of human life or 
health, inter alia  
 
 Commission 
Implementing Regulation 
(EU) 2021/521 of 24 
March 2021 making 
specific arrangements to 
the mechanism making 
the exportation of certain 
products subject to the 
production of an export 
authorisation;  
Official Journal L 104, 
25.03.2021  
 
http://data.eu ropa.eu/eli/r
eg_impl/2021/521/oj  
 
Application period: from 
26.03 .2021 until 
06.05.2021  Administration: 
Competent authorities 
in EU Member States  
 
Authorisations are 
granted to the extent 
that the volume of 
exports is such that it 
does not pose a threat 
to the execution of 
Advance Purchase 
Agreements that the 
European Union has 
concluded with vaccine 
manufacturers.  
 
Authorisations are 
granted where exports 
do not pose a threat to 
the security of supply 
within the European 
Union.  
 
In order to determ ine 
whether the condition 
above is fulfilled, the 
competent authorities 
shall assess the 
following factors:  
 
1) Does the destination 
country restrict its own 
exports of vaccines or 
their raw materials,  
  G/MA/QR/N/EU/5/Add.3  
 
- 4 - QR 
No.  General 
description 
of the 
restriction  Type of 
restriction  Tariff line 
code  (s) 
affected, based 
on HS (2017)  Detailed Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. Other 
International 
Commitments  National legal basis and 
entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
either by law or other 
means?  
 
And 
 
2) Are the condi tions 
prevailing in the 
destination country 
better or worse than the 
EU's, in particular its 
epidemiological 
situation, its vaccination 
rate and its access to 
vaccines?  
 
Exemptions include:  
 
- exports in the context 
of humanitarian aid;  
 
- exports to low and 
middle income countries 
in the COVAX Advance 
Market Commitment 
(AMC) list 
(https://www.gavi.org/ne
ws/media -room/92 -low-
middle -income -
economies -eligible -
access -covid-19-
vaccines -gavi-covax -
amc); 
 
  
  G/MA/QR/N/EU/5/Add.3  
 
- 5 - QR 
No.  General 
description 
of the 
restriction  Type of 
restriction  Tariff line 
code  (s) 
affected, based 
on HS (2017)  Detailed Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. Other 
International 
Commitments  National legal basis and 
entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
       - exports of goods 
purchased and/or 
delivered through 
COVAX, UNICEF and 
PAHO with destination 
to any other COVAX 
participating country;  
 
- EU overseas countries 
and territories;  
 
- Andorra, the Faroe 
Islands, San Marino, 
Vatican City, Büsingen, 
Helgoland, Livigno, 
Ceuta and Melilla.  
 
__________  